Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight‐Based to Flat‐Dosing Strategy
across body-weight ranges. Exposure-response (E-R) analyses revealed no meaningful association between exposure and outcomes. The PopPK model adequately described serplulimab PK and supports transitioning from WT-based to flat-dosing, demonstrating comparable exposure, efficacy, and safety across regimens.
Authors
- Kun Wang (ORCID: https://orcid.org/0000-0003-2609-6058)
- Yuanyuan Shen (ORCID: https://orcid.org/0000-0002-8592-7723)
- Fengyan Xu
- Liang Zhou
- Yaqi Lin
- Qingyu Wang
- Zhihao Kwok
- Chen Hu
Institutions
- Shanghai Huayi Group (China) (CN)
- Viva Biotech (China) (CN)
Publication Details
- Journal
- CPT Pharmacometrics & Systems Pharmacology
- Published
- 2026-03-31
- DOI
- https://doi.org/10.1002/psp4.70204
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00